Review
Published on 28 Jan 2022
PSMA PET in Imaging Prostate Cancer
in Radiation Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.831429
- 41,748 views
- 68 citations
17 articles related to "Biochemical Failure"
Articles
Systematic Review
Published on 12 Oct 2022
Whole-gland high-intensity focused ultrasound ablation and transurethral resection of the prostate in the patients with prostate cancer: A systematic review and meta-analysis
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.988490
- 4,794 views
- 7 citations
Original Research
Published on 02 Sep 2014
Stereotactic Body Radiotherapy as Treatment for Organ Confined Low- and Intermediate-Risk Prostate Carcinoma, a 7-Year Study
in Radiation Oncology
Frontiers in Oncology
doi 10.3389/fonc.2014.00240
- 13,278 views
- 93 citations
Original Research
Published on 05 Jan 2022
Mapping of Recurrence Sites Following Adjuvant or Salvage Radiotherapy for Prostate Cancer Patients
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.787347
- 4,730 views
- 11 citations
Mini Review
Published on 10 Dec 2019
A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2019.01378
- 22,893 views
- 32 citations
Original Research
Published on 08 Jul 2016
Predicting Biochemical Disease-Free Survival after Prostate Stereotactic Body Radiotherapy: Risk-Stratification and Patterns of Failure
in Radiation Oncology
Frontiers in Oncology
doi 10.3389/fonc.2016.00168
- 7,610 views
- 55 citations
Original Research
Published on 28 Oct 2014
Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study
in Radiation Oncology
Frontiers in Oncology
doi 10.3389/fonc.2014.00301
- 18,502 views
- 101 citations
Original Research
Published on 05 Dec 2011
Stereotactic Body Radiation Therapy for Low- and Low-Intermediate-Risk Prostate Cancer: Is there a Dose Effect?
in Radiation Oncology
Frontiers in Oncology
doi 10.3389/fonc.2011.00049
- 8,045 views
- 24 citations
Original Research
Published on 31 Oct 2014
The Early Result of Whole Pelvic Radiotherapy and Stereotactic Body Radiotherapy Boost for High-Risk Localized Prostate Cancer
in Radiation Oncology
Frontiers in Oncology
doi 10.3389/fonc.2014.00278
- 7,982 views
- 38 citations
Original Research
Published on 26 Nov 2021
Two-Weekly High-Dose-Rate Brachytherapy Boost After External Beam Radiotherapy for Localized Prostate Cancer: Long-Term Outcome and Toxicity Analysis
in Radiation Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.764536
- 4,462 views
- 2 citations
Original Research
Published on 11 Nov 2014
SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines
in Radiation Oncology
Frontiers in Oncology
doi 10.3389/fonc.2014.00312
- 12,599 views
- 29 citations
Original Research
Published on 29 May 2020
Whole Pelvic Radiotherapy With Stereotactic Body Radiotherapy Boost vs. Conventionally Fractionated Radiotherapy for Patients With High or Very High-Risk Prostate Cancer
in Radiation Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.00814
- 5,783 views
- 9 citations
Original Research
Published on 06 May 2016
Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience
in Radiation Oncology
Frontiers in Oncology
doi 10.3389/fonc.2016.00114
- 6,425 views
- 32 citations
Original Research
Published on 23 Aug 2016
The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups
in Radiation Oncology
Frontiers in Oncology
doi 10.3389/fonc.2016.00184
- 9,856 views
- 22 citations
Original Research
Published on 25 Sep 2020
Favorable Biochemical Freedom From Recurrence With Stereotactic Body Radiation Therapy for Intermediate and High-Risk Prostate Cancer: A Single Institutional Experience With Long-Term Follow-Up
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.01505
- 4,190 views
- 2 citations
Original Research
Published on 29 Mar 2022
Urethra Sparing With Target Motion Mitigation in Dose-Escalated Extreme Hypofractionated Prostate Cancer Radiotherapy: 7-Year Results From a Phase II Study
in Radiation Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.863655
- 4,429 views
- 5 citations